Cluster Analysis Identifies Patients With Severe Eosinophilic Asthma Who Achieve Super-Response and Remission With Mepolizumab

Clin Exp Allergy. 2024 Oct 10. doi: 10.1111/cea.14584. Online ahead of print.

Abstract

This study identifies two distinct subgroups of patients with severe eosinophilic asthma who respond differently to mepolizumab. Cluster analysis reveals that patients with a family history of asthma, positive skin prick tests and higher baseline lung function have better treatment outcomes, highlighting the value of personalised treatment strategies.

Keywords: T2‐high phenotype; anti‐IL5; machine learning; mepolizumab; prediction of clinical response; real‐life study; remission; super‐response.